SYS-GLIO
Publikationen
2020
Wu, Y., M. Fletcher, Z. Gu, Q. Wang, B. Costa, A. Bertoni, K.-H. Man, M. Schlotter, J. Felsberg, J. Mangei, M. Barbus, A.-C. Gaupel, W. Wang, T. Weiss, R. Eils, M. Weller, H. Liu, G. Reifenberger, A. Korshunov, P. Angel, P. Lichter, C. Herrmann, and B. Radlwimmer (2020). "Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype." Nat Commun 11(6434): 1–19. doi.org/10.1038/s41467-020-20225-w.
2019
Barthel, F. P., Johnson, K. C., Varn, F. S., Moskalik, A. D., Tanner, G., Kocakavuk, E., Anderson, K. J., Abiola, O., Aldape, K., Alfaro, K. D., Alpar, D., Amin, S. B., Ashley, D. M., Bandopadhayay, P., Barnholtz-Sloan, J. S., Beroukhim, R., Bock, C., Brastianos, P. K., Brat, D. J., Brodbelt, A. R., Bruns, A. F., Bulsara, K. R., Chakrabarty, A., Chakravarti, A., Chuang, J. H., Claus, E. B., Cochran, E. J., Connelly, J., Costello, J. F., Finocchiaro, G., Fletcher, M. N., French, P. J., Gan, H. K., Gilbert, M. R., Gould, P. V., Grimmer, M. R., Iavarone, A., Ismail, A., Jenkinson, M. D., Khasraw, M., Kim, H., Kouwenhoven, M. C. M., LaViolette, P. S., Li, M., Lichter, P., Ligon, K. L., Lowman, A. K., Malta, T. M., Mazor, T., McDonald, K. L., Molinaro, A. M., Nam, D. H., Nayyar, N., Ng, H. K., Ngan, C. Y., Niclou, S. P., Niers, J. M., Noushmehr, H., Noorbakhsh, J., Ormond, D. R., Park, C. K., Poisson, L. M., Rabadan, R., Radlwimmer, B., Rao, G., Reifenberger, G., Sa, J. K., Schuster, M., Shaw, B. L., Short, S. C., Smitt, P. A. S., Sloan, A. E., Smits, M., Suzuki, H., Tabatabai, G., Van Meir, E. G., Watts, C., Weller, M., Wesseling, P., Westerman, B. A., Widhalm, G., Woehrer, A., Yung, W. K. A., Zadeh, G., Huse, J. T., De Groot, J. F., Stead, L. F., Verhaak, R. G. W. and Consortium, G. (2019). "Longitudinal molecular trajectories of diffuse glioma in adults." Nature 576(7785): 112-120. www.ncbi.nlm.nih.gov/pubmed/31748746.
Körber, V. and Höfer, T. (2019). "Inferring growth and genetic evolution of tumors from genome sequences." Current Opinion in Systems Biology 16: 1--9. www.sciencedirect.com/science/article/pii/S2452310019300344.
Korber, V., Yang, J., Barah, P., Wu, Y., Stichel, D., Gu, Z., Fletcher, M. N. C., Jones, D., Hentschel, B., Lamszus, K., Tonn, J. C., Schackert, G., Sabel, M., Felsberg, J., Zacher, A., Kaulich, K., Hubschmann, D., Herold-Mende, C., von Deimling, A., Weller, M., Radlwimmer, B., Schlesner, M., Reifenberger, G., Hofer, T. and Lichter, P. (2019). "Evolutionary Trajectories of IDH(WT) Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis." Cancer Cell. www.ncbi.nlm.nih.gov/pubmed/30905762.
2018
Zuckermann, M., Hlevnjak, M., Yazdanparast, H., Zapatka, M., Jones, D. T. W., Lichter, P.Gronych, J., 2018. A novel cloning strategy for one-step assembly of multiplex CRISPR vectors. Sci Rep, 8(1), 17499. doi.org/10.1038/s41598-018-35727-3
2017
Korshunov, A., Schrimpf, D., Ryzhova, M., Sturm, D., Chavez, L., Hovestadt, V., Sharma, T., Habel, A., Burford, A., Jones, C., Zheludkova, O., Kumirova, E., Kramm, C.M., Golanov, A., Capper, D., von Deimling, A., Pfister, S.M., Jones, D.T.W., 2017. H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Acta Neuropathol. doi.org/10.1007/s00401-017-1710-1
Mohme, M., Maire, C.L., Riecken, K., Zapf, S., Aranyossy, T., Westphal, M., Lamszus, K., Fehse, B., 2017. Optical Barcoding for Single-Clone Tracking to Study Tumor Heterogeneity. Mol. Ther. 25, 621–633. doi.org/10.1016/j.ymthe.2016.12.014
Pusch, S., Krausert, S., Fischer, V., Balss, J., Ott, M., Schrimpf, D., Capper, D., Sahm, F., Eisel, J., Beck, A.-C., Jugold, M., Eichwald, V., Kaulfuss, S., Panknin, O., Rehwinkel, H., Zimmermann, K., Hillig, R.C., Guenther, J., Toschi, L., Neuhaus, R., Haegebart, A., Hess-Stumpp, H., Bauser, M., Wick, W., Unterberg, A., Herold-Mende, C., Platten, M., von Deimling, A., 2017. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathol. 133, 629–644. doi.org/10.1007/s00401-017-1677-y
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C.B., Weller, M., 2017. Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat. Rev. Clin. Oncol. 14, 434–452. doi.org/10.1038/nrclinonc.2016.204
Silva, L.S., Poschet, G., Nonnenmacher, Y., Becker, H.M., Sapcariu, S., Gaupel, A.-C., Schlotter, M., Wu, Y., Kneisel, N., Seiffert, M., Hell, R., Hiller, K., Lichter, P., Radlwimmer, B., 2017. Branched-chain ketoacids secreted by glioblastoma cells via MCT1 modulate macrophage phenotype. EMBO Rep. doi.org/10.15252/embr.201744154
2016
Ernst, A., Jones, D.T.W., Maass, K.K., Rode, A., Deeg, K.I., Jebaraj, B.M.C., Korshunov, A., Hovestadt, V., Tainsky, M.A., Pajtler, K.W., Bender, S., Brabetz, S., Gröbner, S., Kool, M., Devens, F., Edelmann, J., Zhang, C., Castelo-Branco, P., Tabori, U., Malkin, D., Rippe, K., Stilgenbauer, S., Pfister, S.M., Zapatka, M., Lichter, P., 2016. Telomere dysfunction and chromothripsis. Int. J. Cancer 138, 2905–2914. doi.org/10.1002/ijc.30033
International Cancer Genome Consortium PedBrain Tumor Project, 2016. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat. Med. 22, 1314–1320. http://doi.org/10.1038/nm.4204